BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Given Consensus Rating of “Moderate Buy” by Analysts
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Free Report) has earned a consensus rating of “Moderate Buy” from the six brokerages that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 1-year price objective […]
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Free Report) has earned a consensus rating of “Moderate Buy” from the six brokerages that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 1-year price objective […]
